WEATHER ALERT January 27, 2026 (12:00 PM): Due to the recent inclement weather, we are experiencing higher than usual call volume. Your call is important to us. We strongly recommend current patients utilize the Patient Portal to reach their clinical teams with questions or to adjust their appointment if necessary. Messages received in the Patient Portal will be returned as quickly as possible. Thank you for your patience.
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
